secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001447028-24-000066
Event type: litigation
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus and Moderna agree to extend patent trial schedule to Sept 2025
----------------------------------------------------------------------

- Arbutus, Genevant filed stipulation with Moderna extending case schedule in COVID-19 vaccine patent suit.
- Parties request trial start moved to September 24, 2025, subject to court approval.
- Lawsuit seeks damages for patent infringement in manufacture and sale of MRNA-1273.
- Stipulation cites need to accommodate outstanding discovery from Moderna and third parties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000144702824000066/0001447028-24-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000144702824000066/abus-20240805.htm
  HTML page:      https://secwatch.observer/filing/0001447028-24-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer